BB Biotech’s Kite Pharma, Inc. KITE Stock Holding History

BB Biotech’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-640,000	Closed	-$66.3M	–	28
2017 Q2	$66.3M	Sell	640,000 -100,000	-14%	-$8.16M	2.03%	16
2017 Q1	$58.1M	Sell	740,000 -60,000	-8%	-$3.71M	1.9%	15
2016 Q4	$35.9M	Hold	800,000	–	–	1.33%	17
2016 Q3	$44.7M	Buy	800,000 +50,000	+7%	+$2.79M	1.57%	17
2016 Q2	$37.5M	Hold	750,000	–	–	1.48%	18
2016 Q1	$34.4M	Hold	750,000	–	–	1.37%	19
2015 Q4	$46.2M	Hold	750,000	–	–	1.3%	19
2015 Q3	$41.8M	Buy	750,000 +400,000	+114%	+$25.2M	1.32%	20
2015 Q2	$21.3M	Buy	+350,000	New	+$20M	0.58%	26

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech's KITE Position: Q3 2017 in Review

BB Biotech sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 640,000 shares — an estimated $66.3M sold.

BB Biotech first reported a position in KITE in Q2 2015 and held it in 9 quarters. The position peaked at $66.3M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

BB Biotech reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
BB Biotech sold 640,000 Kite Pharma, Inc. shares in Q3 2017, an estimated $66.3M.
BB Biotech first reported a position in Kite Pharma, Inc. in Q2 2015 and held it in 9 quarters.
BB Biotech's Kite Pharma, Inc. position peaked at $66.3M in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on BB Biotech's 13F filing for Q3 2017, filed 13 Nov 2017.